StrataCTX® as a Steroid Sparing Device
ConditionCTCL
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorColumbia University
About this trial
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Ability to sign informed consent document
Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel
Patients with a diagnosis of CTCL who have intractable pruritis
Disqualifiers
Patients currently undergoing radiotherapy
Patients currently receiving oral steroids
Patients who are unable to apply topical medications
Trial design
Treatments tested in this trial
- StrataCTX® gel
Treatment groups
70 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov